Bristol Myers Squibb (CELG-RI) Construction in Progress (2015 - 2026)

Bristol Myers Squibb (CELG-RI) posted quarterly Construction in Progress of $1.5 billion for Q1 2026, down 6.94% YoY from $1.7 billion in Q1 2025, and down 4.82% sequentially from $1.6 billion in Q4 2025.

Bristol Myers Squibb (CELG-RI) Construction in Progress (2015 - 2026) Analysis & Trends

Bristol Myers Squibb has disclosed Construction in Progress across 12 years of filings, most recently posting $1.5 billion for Q1 2026.

  • In Q1 2026, Construction in Progress fell 6.94% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $1.5 billion (down 6.94% YoY), while the FY2025 annual figure was $1.6 billion, up 6.16% from the prior year.
  • Construction in Progress slipped to $1.5 billion in Q1 2026, from $1.6 billion in the prior quarter.
  • Over the last five years, Construction in Progress for CELG-RI reached as high as $1.8 billion in Q2 2025 and fell as low as $800.0 million in Q1 2022.
  • The 5-year median for Construction in Progress is $1.2 billion (2024), against an average of $1.3 billion.
  • Annual changes were most pronounced in 2022 — Construction in Progress soared 54.14% — and 2026, when it declined 6.94%.
  • A 5-year view of Construction in Progress shows it stood at $1.1 billion in 2022, then grew by 2.09% to $1.1 billion in 2023, then jumped by 41.86% to $1.5 billion in 2024, then grew by 6.16% to $1.6 billion in 2025, then fell by 4.82% to $1.5 billion in 2026.
  • According to Business Quant data, Construction in Progress over the past three periods registered $1.5 billion, $1.6 billion, and $1.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Construction in Progress (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn -
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn -
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn -
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn -
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn -
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn -
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn -
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn -
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Bristol Myers Squibb 244.56 Mn -10.21 Bn 8.07 Bn 1.54 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 1.54 Bn
Dec 31, 2025 1.62 Bn
Sep 30, 2025 1.46 Bn
Jun 30, 2025 1.76 Bn
Mar 31, 2025 1.66 Bn
Dec 31, 2024 1.53 Bn
Sep 30, 2024 1.37 Bn
Jun 30, 2024 1.26 Bn
Mar 31, 2024 1.21 Bn
Dec 31, 2023 1.08 Bn
Sep 30, 2023 1.11 Bn
Jun 30, 2023 1.20 Bn
Mar 31, 2023 1.07 Bn
Dec 31, 2022 1.05 Bn
Sep 30, 2022 973.00 Mn
Jun 30, 2022 850.00 Mn
Mar 31, 2022 800.00 Mn
Dec 31, 2021 764.00 Mn
Sep 30, 2021 695.00 Mn
Jun 30, 2021 565.00 Mn